Future development plans include incorporating AI, expanding connectors, and specializing in additional therapeutic areas.

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

Paul Howe, chief commercial officer at Protega Pharma, discusses recent rule changes and how the industry is impacted by them ...